Australia's most trusted
source of pharma news
Posted 5 May 2023 PM
After a long build-up, J&J spin-off Kenvue launched on the New York Stock Exchange, raising more money than expected in its initial public offering and closing the day, up more than 20 per cent.
Initially planning on selling 151.2 million shares for between US$20-23, J&J ended up launching Kenvue by selling 172.8 million shares at US$22 each, raising US$3.8 billion, or AU$5.7 billion. The underwriters have a 30-day option to purchase another 25.9 million shares if they need to, for another US$569.8 million.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.